Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (72) 72
male (50) 50
cardiac & cardiovascular systems (49) 49
female (48) 48
middle aged (44) 44
aged (41) 41
index medicus (38) 38
cholesterol (34) 34
statins (30) 30
simvastatin (29) 29
treatment outcome (29) 29
acute coronary syndromes (27) 27
ezetimibe (22) 22
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (22) 22
abridged index medicus (21) 21
drug therapy (21) 21
cardiovascular (20) 20
risk factors (19) 19
acute coronary syndrome - drug therapy (18) 18
double-blind method (18) 18
efficacy (18) 18
medicine, general & internal (18) 18
risk (18) 18
simvastatin - therapeutic use (18) 18
cholesterol, ldl - blood (17) 17
drug therapy, combination (17) 17
mortality (17) 17
myocardial-infarction (17) 17
cardiovascular disease (16) 16
care and treatment (16) 16
coronary heart disease (16) 16
anticholesteremic agents - therapeutic use (15) 15
cardiac patients (15) 15
clinical trials (15) 15
heart attacks (15) 15
dosage and administration (14) 14
acute coronary syndrome (13) 13
analysis (13) 13
outcomes (13) 13
prevention (13) 13
safety (13) 13
statin therapy (13) 13
adult (12) 12
c-reactive protein (12) 12
health aspects (12) 12
low density lipoproteins (12) 12
simvastatin - administration & dosage (12) 12
events (11) 11
internal medicine (11) 11
lipids (11) 11
prognosis (11) 11
therapy (11) 11
atorvastatin (10) 10
dose-response relationship, drug (10) 10
follow-up studies (10) 10
patients (10) 10
peripheral vascular disease (10) 10
time factors (10) 10
cardiovascular diseases (9) 9
diabetes (9) 9
heart failure (9) 9
heart-disease (9) 9
research (9) 9
acute coronary syndrome - blood (8) 8
animals (8) 8
atherosclerosis (8) 8
cardiovascular diseases - prevention & control (8) 8
clinical outcomes (8) 8
ezetimibe - therapeutic use (8) 8
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (8) 8
patient outcomes (8) 8
stroke (8) 8
tyrosine - analogs & derivatives (8) 8
unstable angina (8) 8
usage (8) 8
acute myocardial-infarction (7) 7
angina pectoris (7) 7
anticholesteremic agents (7) 7
anticholesteremic agents - adverse effects (7) 7
azetidines - therapeutic use (7) 7
cardiology (7) 7
heart (7) 7
heart attack (7) 7
hypolipidemic agents - therapeutic use (7) 7
prospective studies (7) 7
secondary prevention (7) 7
tyrosine - therapeutic use (7) 7
aged, 80 and over (6) 6
anticholesteremic agents - administration & dosage (6) 6
atorvastatin calcium (6) 6
c-reactive protein - analysis (6) 6
cancer (6) 6
cardiovascular agents (6) 6
cardiovascular events (6) 6
cholesterol, ldl (6) 6
clinical-trials (6) 6
confidence intervals (6) 6
coronary artery bypass (6) 6
coronary disease - drug therapy (6) 6
disease (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The authors reply
by Cannon, Christopher P and Blazing, Michael A and Braunwald, Eugene
New England Journal of Medicine, ISSN 0028-4793, 10/2015, Volume 373, Issue 15, pp. 1476 - 1477
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
by Cannon, Christopher P and Blazing, Michael A and Giugliano, Robert P and McCagg, Amy and White, Jennifer A and Theroux, Pierre and Darius, Harald and Lewis, Basil S and Ophuis, Ton Oude and Jukema, J. Wouter and De Ferrari, Gaetano M and Ruzyllo, Witold and De Lucca, Paul and Im, KyungAh and Bohula, Erin A and Reist, Craig and Wiviott, Stephen D and Tershakovec, Andrew M and Musliner, Thomas A and Braunwald, Eugene and Califf, Robert M and IMPROVW-IT Investigators and IMPROVE-IT Investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Liver | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT
by Bohula, Erin A and Bohula, Erin A and Giugliano, Robert P and Giugliano, Robert P and Cannon, Christopher P and Cannon, Christopher P and Zhou, Jing and Zhou, Jing and Murphy, Sabina A and Murphy, Sabina A and White, Jennifer A and White, Jennifer A and Tershakovec, Andrew M and Blazing, Michael A and Blazing, Michael A and Braunwald, Eugene and Braunwald, Eugene
Circulation, ISSN 0009-7322, 2015, Volume 132, Issue 13, pp. 1224 - 1233
Background-Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further... 
acute coronary syndrome | C-reactive protein | secondary prevention | cholesterol, LDL | ezetimibe | LDL | hydroxymethylglutaryl-CoA reductase inhibitors | Cholesterol | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | RANDOMIZED-TRIALS | EFFICACY | SAFETY | RISK | ACUTE CORONARY SYNDROMES | HEART-DISEASE | STATIN THERAPY | INFLAMMATION | CLINICAL-TRIALS | PERIPHERAL VASCULAR DISEASE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Myocardial Infarction - blood | Simvastatin - therapeutic use | Humans | Middle Aged | Male | Cardiovascular Diseases - mortality | Electrocardiography | Cholesterol, LDL - blood | Female | Ezetimibe - therapeutic use | C-Reactive Protein - analysis | Drug Therapy, Combination | Cerebral Revascularization | Double-Blind Method | Comorbidity | Simvastatin - administration & dosage | Treatment Outcome | Ezetimibe - administration & dosage | Acute Coronary Syndrome - blood | Myocardial Revascularization | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Myocardial Infarction - drug therapy | Anticholesteremic Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Biomarkers | Creatinine - blood | Aged | Drug Monitoring
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis
by Preiss, David and Seshasai, Sreenivasa Rao Kondapally and Welsh, Paul and Murphy, Sabina A and Ho, Jennifer E and Waters, David D and DeMicco, David A and Barter, Philip and Cannon, Christopher P and Sabatine, Marc S and Braunwald, Eugene and Kastelein, John J. P and de Lemos, James A and Blazing, Michael A and Pedersen, Terje R and Tikkanen, Matti J and Sattar, Naveed and Ray, Kausik K
JAMA, ISSN 0098-7484, 06/2011, Volume 305, Issue 24, pp. 2556 - 2564
CONTEXT A recent meta-analysis demonstrated that statin therapy is associated with excess risk of developing diabetes mellitus. OBJECTIVE To investigate... 
LDL CHOLESTEROL | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | EFFICACY | ACUTE CORONARY SYNDROMES | 14 RANDOMIZED-TRIALS | SIMVASTATIN | LIPID-LOWERING THERAPY | PROGRESSION | ATORVASTATIN | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Diabetes Mellitus - epidemiology | Humans | Cardiovascular Diseases - epidemiology | Risk | Odds Ratio | Randomized Controlled Trials as Topic | Clinical trials | Diabetes | Drug therapy | Drug dosages | Statins | Meta-analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Beneft of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients with Versus Without Diabetes Mellitus Results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Effcacy International Trial)
by Giugliano, Robert P and Cannon, Christopher P and Blazing, Michael A and Nicolau, José C and Corbalán, Ramón and Pinar, Jindrich and Park, Jeong-Gun and White, Jennifer A and Bohula, Erin A and Braunwald, Eugene
Circulation, ISSN 0009-7322, 04/2018, Volume 137, Issue 15, pp. 1571 - 1582
lipids | diabetes mellitus | ezetimibe | acute coronary syndromes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
by Blazing, Michael A., MD and Giugliano, Robert P., MD, SM and Cannon, Christopher P., MD and Musliner, Thomas A., MD and Tershakovec, Andrew M., MD, MPH and White, Jennifer A., MS and Reist, Craig, PhD and McCagg, Amy, BS and Braunwald, Eugene, MD and Califf, Robert M., MD
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 2, pp. 205 - 212.e1
Background The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) is evaluating the potential benefit for reduction in major... 
Cardiovascular | LDL CHOLESTEROL | PLUS EZETIMIBE | CARDIAC & CARDIOVASCULAR SYSTEMS | INTENSIVE STATIN THERAPY | EFFICACY | SAFETY | AORTIC-STENOSIS | CLINICAL-TRIALS | DISEASE | LOW-DENSITY-LIPOPROTEIN | PLACEBO-CONTROLLED TRIAL | Simvastatin - therapeutic use | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Ezetimibe | Cholesterol, LDL - drug effects | Male | Azetidines - pharmacology | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Acute Coronary Syndrome - complications | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Anticholesteremic Agents - pharmacology | Medical research | Low density lipoproteins | Simvastatin | Cardiac patients | Medicine, Experimental | Coronary heart disease | Antilipemic agents | Heart attacks | Acute coronary syndromes | Drug therapy | Cholesterol | Statins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention
by Bohula, Erin A., MD, DPhil and Morrow, David A., MD, MPH and Giugliano, Robert P., MD, SM and Blazing, Michael A., MD and He, Ping, MS and Park, Jeong-Gun, PhD and Murphy, Sabina A., MPH and White, Jennifer A., MS and Kesaniemi, Y. Antero, MD, PhD and Pedersen, Terje R., MD, PhD and Brady, Adrian J., MD and Mitchel, Yale, MD and Cannon, Christopher P., MD and Braunwald, Eugene, MD
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 8, pp. 911 - 921
Abstract Background Ezetimibe improves cardiovascular (CV) outcomes in patients stabilized after acute coronary syndrome (ACS) when added to statin therapy.... 
Cardiovascular | Internal Medicine | simvastatin | acute coronary syndrome | risk stratification | secondary prevention | ezetimibe | low-density lipoprotein cholesterol | MODERATE | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | EFFICACY | ACUTE CORONARY SYNDROMES | PREVIOUS MYOCARDIAL-INFARCTION | ATORVASTATIN | TRIAL | HEART-DISEASE | STATIN THERAPY | VORAPAXAR | Simvastatin - therapeutic use | Prospective Studies | Risk Assessment | Humans | Middle Aged | Male | Treatment Outcome | Secondary Prevention | Acute Coronary Syndrome - complications | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Acute Coronary Syndrome - therapy | Female | Aged | Ezetimibe - therapeutic use | Myocardial Infarction - prevention & control | Medical colleges | Continuing medical education | Cardiology | Coronary heart disease | Medicine, Preventive | Statins | Cardiovascular agents | Preventive health services | Prevention | Medical research | Low density lipoproteins | Medicine, Experimental | Hypertension | Heart failure | Stroke | Heart attacks | Cardiovascular disease | Lipids | Angina pectoris | Low density lipoprotein | Patients | Cholesterol | Disease prevention | Coronary vessels | Electrocardiography | Population | Diabetes | Kidney diseases | Health risk assessment | Acute coronary syndromes | Age
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights